- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01503450
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
January 4, 2012 updated by: Dr. Reddy's Laboratories Limited
An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fed Conditions
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
Study Overview
Detailed Description
An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fed conditions.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400013
- Wellquest Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy human subjects within the age range of 18 to 45 years
- Non-smokers since at least six months
- Willingness to provide written informed consent to participate in the study
- Body-mass index of ≥18.5 kg/m2 and ≤ 24.9 kg/m2, with body weight not less than 50 kg
- Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
- Normal 12-lead ECG or one with abnormality considered to be clinically insignificant
- Normal chest X-ray PA view
- Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol
Female Subjects
- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams. Jellies, diaphragm, intrauterine device (IUD), or abstinence, or
- postmenopausal for at least 1 year, or
- surgically sterile (bilateral tubal ligation. bilateral oophorectomy, or hysterectomy has been performed on the subject
Exclusion Criteria:
- Personal / family history of allergy or hypersensitivity to olanzapine or allied drugs
- Past history of anaphylaxis or angioedema
- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
- Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
- Any cardiac, renal or liver impairment, any other organ or system impairment
- History of seizure or psychiatric disorders
- Presence of disease markers of HIV 1 and 2, and hepatitis Band C virus
- Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [ one glass Wine, half plnt boor, and one measure (one ounce) of spirit).
- Consumption of xanthine containing derivatives (coffee, tea, cola drinks. chocolate) within 48 hours before check-in of each period
- Use of any recreational drug or a history of drug addiction
- Participation in any clinical trial within the past 3 months
- Inaccessibility of veins in left and right arm
- Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication
- Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs Within the last four weeks
- An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study
- Consumption of grapefruit- containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods
- Recent history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to the study
- Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding
- Having an occupation or requirement of driving a vehicle or operate a complex machinery before 21 days of taking the drug in both periods
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Olanzapine OD Tablets 5 mg
Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
|
Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Other Names:
|
Active Comparator: Zyprexa Zydis 5 mg Tablets
Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
|
Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence is based on Cmax and AUC parameters
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dr. Ghanashyam Rao, MBBS, Wellquest Clinical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
January 2, 2012
First Submitted That Met QC Criteria
January 3, 2012
First Posted (Estimate)
January 4, 2012
Study Record Updates
Last Update Posted (Estimate)
January 5, 2012
Last Update Submitted That Met QC Criteria
January 4, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Malnutrition
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
- BE-171-OLAN-2006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Umeå UniversityUniversity of California; Mead Johnson NutritionActive, not recruitingHealth of Formula-fed Children | Infant Infections in Formula-fed Children | Iron Status of Formula-fed ChildrenSweden
-
Dr. Reddy's Laboratories LimitedCompleted
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
Clinical Trials on Olanzapine OD Tablets 5 mg
-
University of CalgaryNot yet recruitingChronic Migraine
-
Laboratorios Andromaco S.A.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Amani Hassan Abdel-WahabCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
Joint Stock Company "Farmak"Completed
-
BayerMerck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR CentreCompletedChronic Heart Failure With Preserved Ejection FractionSpain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted